Drug intelligence / Profile preview

HepaMer-S

Development stage: Unknown
Lead developer: Merz Therapeutics
Administration: Oral

Overview

HepaMer-S is a veterinary nutraceutical developed by Pepco Pharma, specifically formulated for liver, kidney, and metabolic support in poultry, dairy, and livestock. Administered orally through feed or water, the product is positioned as a performance enhancer and organ support supplement. While the specific active ingredients and molecular mechanisms of action are not publicly detailed by the developer, it is intended to promote hepatic health and metabolic efficiency in various livestock species.

Brand names: HepaMer-S

Beyond the preview

Go deeper on HepaMer-S.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HepaMer-S.

Explore the full profile